Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjögren's Syndrome, Ankylosing Spondylitis, Behçet's Disease
Conditions
Interventions
Sj?gren’s syndrome group:None
Ankylosing spondylitis group:None
Beh?et's disease group:None
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 16 to 75 years; 2.Confirmed diagnosis of a rheumatic or autoimmune disease; (1) Systemic lupus erythematosus (SLE): meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE, with a total score of >=10. (2) Rheumatoid arthritis (RA): meeting the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA, with a score of >= 6. (3) Sjögren’s syndrome (SS): meeting the 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, with a total score of >= 4. (4) Behçet's disease (BD): meeting the 2014 International Criteria for Behçet's Disease (ICBD). (5) Ankylosing spondylitis (AS): meeting the 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria, with either imaging evidence of sacroiliitis (X-ray grade >= bilateral grade II or unilateral grade III) or HLA-B27-positive axial spondyloarthritis. 3.Voluntarily signed the informed consent form; 4.Willing and able to comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1. Recent significant infection or vaccination: Acute infectious disease requiring systemic (oral or intravenous) anti-infective treatment within 4 weeks prior to enrollment, or receipt of any live or inactivated vaccine within 2 weeks prior to enrollment. 2. Severe immunocompromise: Known congenital or acquired immunodeficiency, or current long-term high-dose immunosuppressive therapy, or any condition that, in the investigator's judgment, may significantly affect the viral profile. 3. History of malignancy: Current or history of active malignancy within the past 5 years (excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix). 4. Pregnancy or lactation: To avoid potential interference from the unique immunological status during pregnancy on the study results, women who are pregnant or breastfeeding will be excluded. 5. Other conditions deemed inappropriate for participation by the investigator: Including any serious, uncontrolled psychiatric or neurological disorder that may result in inability to comply with study procedures; or any other condition that, in the investigator's judgment, may confound the study results or place the subject at undue risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virome Sequencing data; | — |
Secondary
| Measure | Time frame |
|---|---|
| Integrative analysis of virome and host genetics; | — |
Countries
China
Contacts
Public ContactYuan Liu
The First Affiliated Hospital of Xiamen University
Outcome results
None listed